FIDMAPI
LIVE

Serial Number

97560297

Owner

Prometheus Biosciences, Inc.

Attorney

Palak Mayani

Filing Date

Aug 23, 2022

Add to watchlist:

No watchlists yet
View on USPTO

FIDMAPI Trademark

Serial Number: 97560297

FIDMAPI is a trademark filed by Prometheus Biosciences, Inc. on August 23, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Prometheus Biosciences, Inc.

3050 Science Park Rd.
San Diego, CA 92037

Entity Type: 03

Trademark Details

Filing Date

August 23, 2022

Registration Date

Not Registered

Published for Opposition

October 10, 2023

Goods & Services

Pharmaceutical preparations used for the treatment of gastrointestinal disorders and diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems, immune modulation and management of side effects associated with renal disorders and cancer

Diagnostic preparations for clinical or medical laboratory use; diagnostic reagents for clinical or medical laboratory use

Medical laboratory services, namely, laboratory testing for scientific research purposes and medical research services; medical laboratory services, namely, laboratory testing for scientific research purposes in the field of disease management and gastrointestinal disorders and diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems; medical laboratory services, namely, laboratory testing for scientific research of immune modulation and management of side effects associated with renal disorders and cancer pathology; medical laboratory services, namely, laboratory testing for scientific research of patient disease diagnoses and for patient selection for clinical trials

Health care services, namely, disease management programs; medical services, namely, providing medical information to health care providers, managed care providers and patients via computer networks; providing health information in the field of gastrointestinal diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems; providing information relating to medical diagnostic testing; providing information relating to medical treatment recommendation; medical consultation; providing a website featuring information about medical services for the diagnosis, prevention, and treatment of gastrointestinal disorders and diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems, immune modulation and management of side effects associated with renal disorders and cancer; medical diagnostic testing provided by medical laboratories; medical analysis services in the nature of laboratory testing for disease management and patient diagnosis and patient selection for the diagnosis and treatment of gastrointestinal disorders and diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems, provided by medical laboratories; medical analysis services relating to the treatment of patients in the nature of laboratory testing for the purpose of immune modulation and management of side effects associated with renal disorders and cancer, provided by medical laboratories

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 28, 2026 EXRA
SOU EXTENSION 5 GRANTED
May 27, 2026 EX5G
SOU EXTENSION 5 FILED
May 26, 2026 EXT5
SOU TEAS EXTENSION RECEIVED
May 26, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 23, 2025 EXRA
SOU EXTENSION 4 GRANTED
Oct 22, 2025 EX4G
SOU EXTENSION 4 FILED
Oct 22, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 22, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2025 EXRA
SOU EXTENSION 3 GRANTED
May 27, 2025 EX3G
SOU EXTENSION 3 FILED
May 27, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
May 27, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 15, 2025 EXRA
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 15, 2025 AITU
SOU EXTENSION 2 GRANTED
Feb 14, 2025 EX2G
SOU EXTENSION 2 FILED
Jan 13, 2025 EXT2
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jan 13, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 13, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 13, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 13, 2025 REAP
SOU TEAS EXTENSION RECEIVED
Nov 19, 2024 EEXT
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Nov 11, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 11, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 11, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 11, 2024 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 14, 2024 EXRA
SOU EXTENSION 1 GRANTED
May 13, 2024 EX1G
SOU EXTENSION 1 FILED
May 13, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
May 13, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 5, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 10, 2023 NPUB
PUBLISHED FOR OPPOSITION
Oct 10, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 20, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 6, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 6, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 6, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 6, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 6, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 23, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 22, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 22, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 13, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 13, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 13, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 9, 2023 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 3, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 3, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 3, 2023 REAP
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 12, 2022 NWOS
NEW APPLICATION ENTERED
Aug 26, 2022 NWAP